Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...
Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.Please watch the video at Investors.com - The Weight-Loss ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
In a press release, Lilly announced that in its latest trial comparing its medication, Zepbound, to Wegovy, made by Novo ...
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...